Wetherby Asset Management Inc. Buys 108 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wetherby Asset Management Inc. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 4.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,418 shares of the biopharmaceutical company’s stock after purchasing an additional 108 shares during the quarter. Wetherby Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,689,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of REGN. Core Alternative Capital lifted its position in shares of Regeneron Pharmaceuticals by 800.0% in the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 32 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $33,000. Byrne Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $34,000. Addison Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 220.0% in the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 33 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in shares of Regeneron Pharmaceuticals by 83.3% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 55 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 25 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on REGN shares. Cowen raised their price objective on Regeneron Pharmaceuticals from $635.00 to $645.00 in a research report on Wednesday, July 20th. StockNews.com cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an “overweight” rating for the company in a report on Friday, June 3rd. Morgan Stanley raised Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $625.00 to $851.00 in a report on Friday. Finally, SVB Leerink lifted their price target on Regeneron Pharmaceuticals from $630.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $727.78.

Insider Activity

In other news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 1st. The stock was sold at an average price of $587.76, for a total value of $646,536.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at approximately $11,545,957.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 1st. The stock was sold at an average price of $587.76, for a total value of $646,536.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at approximately $11,545,957.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 10,453 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $621.29, for a total value of $6,494,344.37. Following the sale, the director now owns 18,408 shares in the company, valued at approximately $11,436,706.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,435 shares of company stock worth $31,663,304. Insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.2 %

Shares of REGN opened at $724.32 on Monday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $754.67. The business’s fifty day moving average is $607.57 and its 200-day moving average is $636.33. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12. The firm has a market cap of $78.96 billion, a price-to-earnings ratio of 14.46, a PEG ratio of 2.52 and a beta of 0.29.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter in the previous year, the business posted $27.97 EPS. The company’s revenue for the quarter was down 44.4% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.97 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.